Pfizer impresses cardio crowd with mortality and hospitalization rates for tafamidis in ATTR-CM -- but Alnylam quickly blasts back
Pfizer has scored the kind of potentially game-changing pivotal data for tafamidis in rare cases of transthyretin amyloid cardiomyopathy that analysts have been on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
